RECOGNITION AND ASSESSMENT

Symptoms and signs

  • Coffee-ground vomit
    • dark brown, denatured blood in vomit
  • Haematemesis
    • bright red or clotted blood in vomit
  • Melaena
    • black, tarry, smelly stool containing digested blood
  • Postural dizziness or fainting
  • Evidence of severe bleeding defined as:
    • clammy skin
    • shock with tachycardia (heart rate >100 beats/min)
    • hypotension (systolic BP <100 mmHg)
    • postural hypotension in patient who is not clinically shocked
  • Evidence of anaemia
  • Features of precipitating disease
    • jaundice, stigmata of liver disease
  • Features of bleeding disorder (petechiae)
  • Buccal or facial telangiectasia
  • Bright red rectal bleeding in the absence of hypotension is likely from lower GI tract

Previous history

  • Enquire about:
    • peptic ulceration
    • previous bleeds
    • liver disease
    • family history of bleeding
    • ulcerogenic medication/anticoagulants
    • alcohol
    • weight loss

ASSESSMENT OF RISK


Categorise patients according to their risk of death/rebleeding
Guidance on risk using the Glasgow Blatchford score

Select as many of list below that apply to your patient

Each selected will add to the Glasgow Blatchford score for severity of bleeding


Investigations

All

  • FBC
  • U&E

Non-severe bleeding

  • Group and save (non-urgent)

Severe bleeding

  • INR
  • LFTs
  • Crossmatch (4 units)
    • notify blood transfusion laboratory of clinical problem and degree of urgency

MANAGEMENT PATHWAYS

Back to Pathway Choice

PATIENTS FOR POSSIBLE DISCHARGE


To assess you are using correct guideline, see Assessment of risk flowchart
  • Send to observation unit

Observations

2-hrly

  • Heart rate
  • BP: lying and standing at 3 min

Investigations

  • FBC
  • U&E
  • Group and save (non-urgent)
  • Repeat FBC and U&E 4 hr after admission to CDU

Treatment

  • None, unless specific cause or increase in severity identified

Review after 6 hr

Admission criteria

  • Glasgow Blatchford score ≥1
  • Further episode of GI bleed
  • Haemodynamic instability
  • Abnormal blood results

Criteria for discharge and outpatient OGD

  • Glasgow Blatchford score 0
  • No co-morbidities requiring acute admission
  • Patient information pack provided to patient
  • Request outpatient OGD
  • Give patient copy of discharge letter
Back to Pathway Choice

NON-SEVERE NON-VARICEAL BLEEDING


To assess you are using correct guideline, see Assessment of risk flowchart
  • Baseline observations
  • Order upper GI endoscopy within 24 hr/next available endoscopy list
  • Wide bore IV access
  • Allow food and drink until 4 hr before endoscopy
  • No treatment necessary before endoscopy
  • Send patient to acute GI unit

Investigations

  • FBC
  • U&E
  • INR
  • LFTs
  • Crossmatch (4 units)
    • notify blood transfusion laboratory of clinical problem and degree of urgency

Subsequent management

  • Continue observations until outcome of upper GI endoscopy is known
  • Follow advice on the endoscopy report

Preferred eradication regimen for Helicobacter pylori

  • Give for 7 days
    • absolute compliance with regimen essential for an eradication rate of 90%
    • if ulcer large, or complicated by haemorrhage or perforation, continue omeprazole for a further 21 days

Not allergic to penicillin

  • Omeprazole 20 mg oral 12-hrly
  • Amoxicillin 1 g oral 12-hrly
  • Metronidazole 400 mg oral 12-hrly

Patients allergic to penicillin

  • Omeprazole 20 mg oral 12hrly
  • Clarithromycin 250 mg oral 12hrly
  • Metronidazole 400 mg oral 12hrly
  • Simvastatin contraindicated with clarithromycin 

After eradication of Helicobacter pylori

  • If NSAID therapy reintroduced, continue omeprazole 20 mg oral daily for as long as NSAID required
  • If neoplasm identified, refer to upper GI cancer team

Patients who rebleed

  • If an otherwise stable patient who is potentially referable for surgery rebleeds, request urgent endoscopy
    • discuss with on-call surgical team

 Indications for surgical intervention

  • Exsanguinating haemorrhage
    • too fast to replace
  • Failed endoscopic therapy
  • Major rebleed after successful endoscopic therapy
  • In special situations, a major bleed may warrant early surgery
    • e.g. patients with rare blood group or patients refusing blood transfusion
  • Once agreed with surgical team, transfer high-risk patients to surgery

Monitor

  • 4-hrly heart rate and BP
  • Observe vomit for blood content and stool chart for melaena
  • Daily Hb until it is stable (not falling)
  • In patients with severe bleeding, urine output
    • aim for >30 mL/hr

Discharge and follow-up

  • Discharge when stable

H. pylori positive duodenal ulcer

  • Ask GP to arrange faecal antigen testing for H pylori >4 weeks after completing eradication therapy

If H.pylori positive gastric ulcer

  • Ask GP to arrange:
    • faecal antigen testing for H pylori >4 weeks after completion of eradication therapy
    • repeat upper GI endoscopy to check healing 6–8 weeks following discharge
  • If Hb still <100 g/L, start ferrous sulphate 200 mg oral 8-hrly

Non-severe bleeding with transient pathology (e.g. Mallory–Weiss tear, acute erosion)

  • Discharge promptly after endoscopy with no follow-up

Non-severe bleeding and ulcer-related disease

  • Discharge young stable patients (aged <45-yrs) promptly after endoscopy
  • Discharge older patients (aged >45-yrs) when their condition is stable

Severe bleeding and ulcer-related disease

  • Discharge when condition and Hb stable

Neoplasia

  • Discuss further investigation and treatment with upper GI cancer team
Back to Pathway Choice

SEVERE NON-VARICEAL BLEEDING


To assess you are using correct guideline, see Assessment of risk

Investigations

  • FBC
  • U&E
  • INR
  • LFTs
  • Crossmatch (4 units)
    • notify blood transfusion laboratory of clinical problem and degree of urgency

Replace fluid loss and restore BP

Logistics

  • Insert 2 large bore (14–16 G) venous cannulae
  • In patients with significant cardiac disease, consider CVP line to guide IV fluid replacement
  • If not already an inpatient, admit
  • Keep patient nil-by-mouth

Treatment

  • Stop antihypertensives, diuretics, NSAIDs, anticoagulants
  • Infuse compound sodium lactate (Hartmann’s) solution or sodium chloride 0.9% 1–2 L over 30–120 min to achieve systolic BP >100 mmHg
  • Transfuse as soon as blood available. See Blood and blood products guidelines
    • prefer packed cells
    • if 50% of total blood volume loss in 3 hr, follow Massive haemorrhage protocol with blood bank to obtain blood products rapidly

Other initial management

  • Once resuscitation has begun, give omeprazole 80 mg by IV infusion over 40–60 min
    • then by continuous IV infusion of 40 mg in 100 mL sodium chloride 0.9% at 20 mL/hr (8 mg/hr) for 72 hr
  • Arrange upper GI endoscopy
    • contact gastroenterology

Surgical intervention

  • After preliminary resuscitation, discuss all patients with severe non-variceal bleeding with on-call surgical team
    • if appropriate, transfer patient to general surgical care for further management
  • If doubt about realistic possibility of surgery, duty surgeon and duty physician to review patient in consultation
  • If any difficulties are encountered with this policy, inform on-call consultant physician
    • contact a senior gastroenterologist only if on-call team unable to resolve the clinical management problem satisfactorily with duty surgical team
  • Indications for surgical intervention or interventional radiology under surgical care are:
    • exsanguinating haemorrhage (too fast to replace or requiring >4 units of blood to restore blood pressure)
    • failed medical therapy
    • special situation (e.g. patients with rare blood group or refusing blood transfusions)

Subsequent management

  • Continue observations until know outcome of upper GI endoscopy
  • Follow advice on the endoscopy report

Preferred eradication regimen for Helicobacter pylori

  • Give for 7 days
    • absolute compliance with regimen essential for an eradication rate of 90%
    • if ulcer large, or complicated by haemorrhage or perforation, continue omeprazole for a further 21 days

Not allergic to penicillin

  • Omeprazole 20 mg oral 12-hrly
  • Amoxicillin 1 g oral 12-hrly
  • Metronidazole 400 mg oral 12-hrly

Patients allergic to penicillin

  • Omeprazole 20 mg oral 12hrly
  • Clarithromycin 250 mg oral 12hrly
  • Metronidazole 400 mg oral 12hrly
  • Simvastatin contraindicated with clarithromycin

After eradication of Helicobacter pylori

  • If NSAID therapy reintroduced, continue omeprazole 20 mg oral daily for as long as NSAID required
  • If neoplasm identified, refer to upper GI cancer team

Patients who rebleed

  • If an otherwise stable patient who is potentially referable for surgery rebleeds, request urgent endoscopy
    • discuss with on-call surgical team

Indications for surgical intervention

  • Exsanguinating haemorrhage
    • too fast to replace
  • Failed endoscopic therapy
  • Major rebleed after successful endoscopic therapy
  • In special situations, a major bleed may warrant early surgery
    • e.g. patients with rare blood group or patients refusing blood transfusion
  • Once agreed with surgical team, transfer high-risk patients to surgery

Monitor

  • 4-hrly heart rate and BP
  • Observe vomit for blood content and stool chart for melaena
  • Daily Hb until it is stable (not falling)
  • In patients with severe bleeding, urine output
    • aim for >30 mL/hr

Discharge and follow-up

  • Discharge when stable

H.pylori positive duodenal ulcer

  • Ask GP to arrange faecal antigen testing for H pylori >4 weeks after completing eradication therapy

If H.pylori positive gastric ulcer

  • Ask GP to arrange:
    • faecal antigen testing for H pylori >4 weeks after completion of eradication therapy
    • repeat upper GI endoscopy to check healing 6–8 weeks following discharge
  • If Hb still <100 g/L, start ferrous sulphate 200 mg oral 8-hrly

Non-severe bleeding with transient pathology (e.g. Mallory–Weiss tear, acute erosion)

  • Discharge promptly after endoscopy with no follow-up

Non-severe bleeding and ulcer-related disease

  • Discharge young stable patients (aged <45-yrs) promptly after endoscopy
  • Discharge older patients (aged >45-yrs) when their condition is stable

Severe bleeding and ulcer-related disease

  • Discharge when condition and Hb stable

Neoplasia

  • Discuss further investigation and treatment with upper GI cancer team
Back to Pathway Choice

OESOPHAGEAL VARICEAL BLEEDING


To check you are using correct guideline, see Assessment of risk flowchart

Investigations

  • FBC
  • U&E
  • INR
  • LFTs
  • Crossmatch (4 units)
    • notify blood transfusion laboratory of clinical problem and degree of urgency

Fluid and controlling haemorrhage

  • Haemorrhage from oesophageal varices is always life-threatening

Logistics

  • Insert 2 large bore (14–16 G) IV cannulae, 1 in each antecubital fossa
  • In patients with significant cardiovascular disease, a CVP line is advisable

Treatment

  • Initially infuse sodium chloride 0.9% 1 L over 2–4 hr:
    • if Hb <100 g/L, transfuse 1 unit of blood for every 10 g/L <100 g/L. See Blood and blood products guideline
  • Correct raised INR with fresh frozen plasma
    • prothrombin complex concentrate recommended for major bleeding associated with warfarin-see BLEEDING/OVER-ANTICOAGULATION: WARFARIN guideline
  • Continue fluid replacement but avoid rapid fluid replacement as it increases risk of rebleeding
  • Aim to restore heart rate <100 beats/min, systolic BP >80 mmHg and Hb ≥100 g/L
  • If haemorrhage still not controlled, discuss with gastroenterology team

Other initial management

  • Contact gastroenterology to arrange upper GI endoscopy
  • Whilst awaiting endoscopy, give terlipressin 2 mg IV bolus
    • then 1 mg 6-hrly, duration directed by endoscopist

Antimicrobials

  • Always obtain blood culture before giving an antimicrobial
    • see Collection of blood culture specimens guideline
  • If septic, see Sepsis guideline

Penicillin Allergy

  • True penicillin allergy is rare
  • Ask the patient and record what happened when they were given penicillin
  • If any doubt about whether patient is truly allergic to penicillin, seek advice from a microbiologist or consultant in infectious diseases
Only accept penicillin allergy as genuine hypersensitivity if convincing history of either rash within 72 hr of dose or anaphylactic reaction

Infection Control alerts

  • Check for IC alert
    • if IC alert not available, check previous 12 months of microbiology reports
  • If MRSA present, treat as tagged for MRSA. See MRSA management
  • If ESBL, MGNB, CARB present, treat as tagged for ESBL. See ESBL/MGNB/CARB management

Not penicillin allergic

  • Give co-amoxiclav 625 mg oral or if nil-by-mouth, 1.2 g IV 8-hrly for 3 days

Penicillin allergic patients

  • Give aztreonam 1 g IV 8-hrly and metronidazole oral 400 mg 8-hrly
    • if nil-by-mouth, 500 mg IV by infusion 8-hrly for 3 days

Previously MRSA colonised

  • Add vancomycin IV by infusion. See Vancomycin guideline

Encephalopathy

  • In patients with grade 4 encephalopathy, see Acute liver failure guideline
  • Discuss endotracheal intubation with gastroenterology
    • if decided to intubate, contact critical care team
  • If not already inpatient, admit
  • Contact gastroenterology team for advice on further management

Monitor

  • 4-hrly heart rate and BP
  • Observe vomit for blood content and stool chart for melaena
  • Daily Hb until it is stable (not falling)
  • In patients with severe bleeding, urine output
    • aim for >30 mL/hr

DISCHARGE AND FOLLOW-UP

  • Discharge when stable
  • Start propranolol 40 mg oral 12-hrly, unless contraindicated
    • prophylaxis for further variceal bleeding
  • Refer to Liver specialist for follow-up

© 2022 The Bedside Clinical Guidelines Partnership.

Created by University Hospital North Midlands and Keele University School of Computing and Mathematics.

Research and development team: James Mitchell, Ed de Quincey, Charles Pantin, Naveed Mustfa